Tue, 16 September 2014
Will the success seen for stage IV patients receiving targeted therapies translate into cure for stage III patients? Dr. Daniel Morgensztern of the Washington University School of Medicine talks about what research is ongoing to answer that question.
Direct download: GRACEcast-266_Lung-Video_IASLC_Morgensztern_Stage_III_Targeted_Rx.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PST